UroGen Pharma Ltd. (NASDAQ:URGN) Insider Mark Schoenberg Sells 4,551 Shares

UroGen Pharma Ltd. (NASDAQ:URGN) insider Mark Schoenberg sold 4,551 shares of the firm’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $50,698.14. Following the completion of the transaction, the insider now owns 145,666 shares of the company’s stock, valued at approximately $1,622,719.24. The trade was a 3.03 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

UroGen Pharma Price Performance

URGN opened at $10.95 on Friday. The firm has a fifty day moving average price of $11.08 and a 200 day moving average price of $12.60. UroGen Pharma Ltd. has a 1 year low of $9.78 and a 1 year high of $20.70. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77.

UroGen Pharma (NASDAQ:URGN) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.55) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.29. The firm had revenue of $25.20 million during the quarter, compared to analyst estimates of $24.22 million. During the same quarter last year, the company posted ($0.68) EPS. On average, research analysts anticipate that UroGen Pharma Ltd. will post -3.12 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on URGN. EF Hutton Acquisition Co. I raised shares of UroGen Pharma to a “strong-buy” rating in a research report on Monday, October 14th. Oppenheimer reissued an “outperform” rating and set a $40.00 target price on shares of UroGen Pharma in a report on Wednesday, October 16th. HC Wainwright restated a “buy” rating and set a $60.00 target price on shares of UroGen Pharma in a research report on Tuesday, October 15th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $25.00 price target on shares of UroGen Pharma in a research report on Thursday, January 23rd. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $43.70.

Hedge Funds Weigh In On UroGen Pharma

Large investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. grew its holdings in UroGen Pharma by 90.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company’s stock valued at $103,000 after purchasing an additional 3,856 shares during the period. BNP Paribas Financial Markets lifted its position in shares of UroGen Pharma by 221.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock valued at $109,000 after buying an additional 5,890 shares in the last quarter. Oppenheimer & Co. Inc. acquired a new stake in UroGen Pharma in the 4th quarter valued at $126,000. Intech Investment Management LLC purchased a new stake in UroGen Pharma in the 3rd quarter worth $155,000. Finally, Verition Fund Management LLC acquired a new position in UroGen Pharma during the third quarter worth $168,000. Institutional investors and hedge funds own 91.29% of the company’s stock.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.